Human papillomavirus 6/11 vaccine recombinant bivalent - Xiamen Innovax

Drug Profile

Human papillomavirus 6/11 vaccine recombinant bivalent - Xiamen Innovax

Alternative Names: Gecolin; Human papillomavirus (types 6 and 11) L1 virus-like particle vaccine - Xiamen Innovax; Human papillomavirus 6/11 bivalent vaccine - Xiamen; Human papillomavirus 6/11 vaccine - Xiamen; Recombinant human papillomavirus type 6/11 bivalent vaccine - Xiamen Innovax

Latest Information Update: 24 Mar 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Xiamen Innovax Biotech
  • Developer Beijing Wantai Bio-pharm; Xiamen Innovax Biotech; Xiamen University
  • Class Cancer vaccines; Papillomavirus vaccines; Synthetic vaccines; Virus-like particle vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Condylomata acuminata

Most Recent Events

  • 12 Mar 2016 Xiamen Innovax Biotech, Beijing Wantai Bio-pharm and Xiamen University plan a phase II trial for Condylomata acuminata (Prevention, In volunteers) in China (IM) (NCT02710851)
  • 01 Mar 2015 Preclinical trials in Condylomata acuminata in China (IM)
  • 01 Mar 2015 Xiamen Innovax and Beijing Wantai Bio-pharm plan a phase I trial for Condylomata acuminata (Prevention) in China (NCT02405520)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top